Kura Oncology’s (KURA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research note released on Thursday morning,Benzinga reports. The firm currently has a $40.00 target price on the stock. HC Wainwright also issued estimates for Kura Oncology’s Q1 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.78) EPS.

KURA has been the topic of several other reports. Bank of America lowered their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. BTIG Research downgraded Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Wedbush boosted their price target on shares of Kura Oncology from $34.00 to $36.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Finally, TD Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA opened at $7.65 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 1 year low of $6.98 and a 1 year high of $24.17. The firm has a market capitalization of $594.89 million, a PE ratio of -3.24 and a beta of 0.78. The business’s 50 day moving average price is $8.19 and its 200-day moving average price is $13.92.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million. As a group, equities research analysts expect that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,729 shares of company stock valued at $92,307. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC increased its position in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after acquiring an additional 3,061 shares during the period. Harbor Advisors LLC purchased a new stake in Kura Oncology during the 4th quarter worth about $87,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology in the 4th quarter valued at about $90,000. Corton Capital Inc. purchased a new position in shares of Kura Oncology in the 4th quarter valued at about $99,000. Finally, Optimize Financial Inc acquired a new position in shares of Kura Oncology during the fourth quarter worth about $100,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.